NASDAQ:DXCM - Dexcom Stock Price, Price Target & More

Dexcom trades on the NASDAQ under the ticker symbol "DXCM."

Dexcom (NASDAQ:DXCM) issued its earnings results on Wednesday, May, 2nd. The medical device company reported ($0.32) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.32). The medical device company earned $184.40 million during the quarter, compared to analysts' expectations of $172.66 million. Dexcom had a negative return on equity of 9.32% and a negative net margin of 4.30%. Dexcom's revenue was up 29.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.49) earnings per share. View Dexcom's Earnings History.

Dexcom is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Dexcom.

19 equities research analysts have issued 12 month price targets for Dexcom's stock. Their forecasts range from $40.00 to $100.00. On average, they expect Dexcom's stock price to reach $69.7941 in the next twelve months. View Analyst Ratings for Dexcom.

Dexcom saw a decline in short interest in May. As of May 15th, there was short interest totalling 9,759,794 shares, a decline of 21.3% from the April 30th total of 12,398,444 shares. Based on an average daily trading volume, of 1,605,191 shares, the short-interest ratio is currently 6.1 days. Approximately 11.4% of the shares of the stock are short sold.

Some companies that are related to Dexcom include Abiomed (ABMD), ResMed (RMD), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Penumbra (PEN), Cantel Medical (CMD), Insulet (PODD), Globus Medical (GMED), Haemonetics (HAE), Merit Medical Systems (MMSI), NovoCure (NVCR), NuVasive (NUVA), Nevro (NVRO) and iRhythm (IRTC).

News stories about DXCM stock have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Dexcom earned a media sentiment score of 0.21 on Accern's scale. They also assigned media headlines about the medical device company an impact score of 47.67 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Dexcom's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (6.15%), BlackRock Inc. (4.41%), JPMorgan Chase & Co. (2.94%), OppenheimerFunds Inc. (1.70%), Franklin Resources Inc. (1.33%) and Point72 Asset Management L.P. (1.11%). Company insiders that own Dexcom stock include Andrew K Balo, Barbara Kahn, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jonathan T Md Lord, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for Dexcom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Russell Investments Group Ltd., Massachusetts Financial Services Co. MA, Baillie Gifford & Co., Compagnie Lombard Odier SCmA, Thornburg Investment Management Inc., Allianz Asset Management GmbH and Allianz Asset Management GmbH. Company insiders that have sold Dexcom company stock in the last year include Andrew K Balo, Barbara Kahn, Jacob Steven Leach, Jay S Skyler, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven Robert Pacelli and Terrance H Gregg. View Insider Buying and Selling for Dexcom.

DXCM stock was purchased by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Point72 Asset Management L.P., Neuberger Berman Group LLC, Federated Investors Inc. PA, JPMorgan Chase & Co., Columbus Circle Investors, Frontier Capital Management Co. LLC and Chicago Capital LLC. View Insider Buying and Selling for Dexcom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $87.48.

Dexcom has a market capitalization of $7.60 billion and generates $718.50 million in revenue each year. The medical device company earns $-50,200,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Dexcom employs 2,990 workers across the globe.

Dexcom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]